Retrospective validation.

Below is a formal retrospective analysis of historical compounds subjected to regulatory withdrawal, isolated computationally prior to wet-lab exposure.

Asset analysis: Terfenadine

Clinical outcome: FDA withdrawal following induction of drug-induced long QT syndrome.

Architecture output: Rejection

Isolated liability pathway: Potassium voltage-gated channel (hERG)

Panel target ID: CHEMBL240

> STATUS: VISUAL ISOLATION SEQUENCE PENDING...

Asset analysis: Troglitazone

Clinical outcome: Global post-market withdrawal following acute liver failure.

Architecture output: Rejection

Isolated liability pathway: Bile salt export pump (BSEP) / CYP450 complex

Panel target ID: CHEMBL6020

> STATUS: VISUAL ISOLATION SEQUENCE PENDING...